• Company
  • Products
  • Medical education
  • News & events
  • Contact Sales

We can help!

Contact one of our representatives or attend our medical education courses.

  • Questions url
  • Medical book icon
  • Envelope icon
  • Company
    • About Bioceramed

    • Contact Us

    • Careers

    • Social Responsibility

    • Projects

  • Products
    • Bone Grafts

    • Platelet-Rich Plasma & Fibrin

    • Hyaluronic Acid

    • Membranes

  • Get in touch
    • Questions or feedback?

      We’d love to hear from you

  • An Hydrumedical company
Co-financed by
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b5x5LeNNTw9rd_Portugal2020.svg
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b5h5LeNNTw9rc_Norte2020.svg
  • https://bioceramed.cdn.prismic.io/bioceramed/Zo2b6R5LeNNTw9re_UE.svg?auto=compress,format
  • https://images.prismic.io/bioceramed/aOzQO55xUNkB14SM_Pessoas2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aMPVYGGNHVfTPFAL_Compete2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aOzP6p5xUNkB14SF_Portugal2030.png?auto=format%2Ccompress&w=132&h=40
  • https://images.prismic.io/bioceramed/aMPVamGNHVfTPFAM_UE.png?auto=format%2Ccompress&w=132&h=40

© 2026 Bioceramed

  • Terms and Conditions
  •   |  Privacy policy
  •   |  Cookies policy
Medical Education
Healvisco® Tendon in Rotator Cuff Tendinopathy
Sep, 08 - 20261 min. read

Healvisco® Tendon in Rotator Cuff Tendinopathy: Twelve-Month Clinical Results

Healvisco® Tendon is a sterile injectable hyaluronic acid gel of non-animal origin, manufactured by Biovico Sp. z o.o. in Poland and distributed by Bioceramed. This clinical evidence summary presents the twelve-month results of a prospective, single-centre, single-arm study conducted at a trauma and orthopaedic surgery clinic in Kielce, Poland.

Ten patients with shoulder pain due to rotator cuff tendinopathy received two peritendinous injections of 1.6% sodium hyaluronate, seven days apart. Pain was assessed with the Visual Analogue Scale and upper limb function with the DASH questionnaire, across seven time points over one year.

Both scores decreased after the first injection. Statistical significance against baseline was reached from 60 days onward and was maintained at the twelve-month assessment. No adverse events, serious adverse events, infections, or allergic reactions were reported.

Seven of the ten patients completed follow-up. The full document sets out the results in detail, together with all study limitations.

  • Download

    Access the Full Document